Question

I am a breastfeeding mother and i want to know if it is safe to use 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile? Is 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile safe for nursing mother and child? Does 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile extracts into breast milk? Does 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile has any long term or short term side effects on infants? Can 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile influence milk supply or can 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile decrease milk supply in lactating mothers?

Answer by DrLact: About 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile usage in lactation

No information is available on the clinical use of 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile during breastfeeding. If 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile is required by the mother, it is not a reason to discontinue breastfeeding.[1] However, until more data become available, 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile should be used with caution during breastfeeding and an alternate drug may be preferred, especially while nursing a newborn or preterm infant.[2] The manufacturer recommends that breastfeeding be discontinued during 3-((3R,4R)-4-Methyl-3-(methyl(7H-pyrrolo(2,3-d)pyrimidin-4-yl)amino)piperidin-1-yl)-3-oxopropanenitrile therapy and for 18 hours after the last dose of Xeljanz or 36 hours after the last dose of Xeljanz XR.

Alternate Drugs

Rituximab(Low Risk)
Penicillamine(Low Risk)
Auranofin(Low Risk)
Leflunomide(Dangerous)
Tocilizumab(Low Risk)
Anakinra(Low Risk)
Methotrexate(Low Risk)
Abatacept(Low Risk)
Dasatinib(Unsafe)
Orlistat(Low Risk)
Gemcitabine(Dangerous)
Nilotinib(Unsafe)
Erlotinib(Unsafe)
Imatinib(Unsafe)
Pazopanib(Unsafe)
Dasatinib(Unsafe)
Nilotinib(Unsafe)
Erlotinib(Unsafe)
Imatinib(Unsafe)
Pazopanib(Unsafe)
Nilotinib(Unsafe)
Erlotinib(Unsafe)
Imatinib(Unsafe)
Pazopanib(Unsafe)
Dasatinib(Unsafe)
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. We do not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.